Can Psilocybin-Assisted Therapy Reduce Depression in Advanced Lung Cancer?
Expert Perspectives
By Keira Smith
Published
Patients diagnosed with advanced lung cancer can experience severe emotional complications, including major depressive disorder, anxiety, and profound existential distress. Despite the widespread availability of traditional antidepressants and conventional psychotherapy, current therapeutic options often fail to adequately relieve psychiatric distress in this population. In this interview, Alan Davis, PhD, Associate Professor and Director of the Center for Psychedelic Drug Research and Education at The Ohio State University, discusses the first clinical trial evaluating psilocybin-assisted therapy specifically in patients with lung cancer. He outlines the structured therapeutic model, initial safety and clinical signals, and how addressing mental health may influence systemic outcomes such as treatment adherence and systemic inflammation.
Unmet Psychiatric Needs in Advanced Lung Cancer
The diagnosis of advanced-stage lung cancer carries a demanding clinical trajectory that frequently precipitates severe psychiatric comorbidities. Because lung malignancies are predominantly detected at advanced stages later in life, patients face an acute existential burden alongside physically demanding antineoplastic therapies.
“Unfortunately, that means the prognosis can be quite difficult, which often leads to existential distress, anxiety, and depression,” explained Dr. Davis. “And unfortunately, the current treatments that we have don't fully meet the needs of this patient population. We're studying psilocybin therapy as an approach that might not only help people feel less depressed, but also hopefully help them enjoy their life better.”
Building upon his previous work directing randomized trials in major depressive disorder and trauma, Dr. Davis described cancer as a form of ongoing trauma. Adapting psychedelic-assisted protocols to oncology aims to relieve existential suffering while directly evaluating the safety and feasibility of these interventions in medically complex cohorts.
The Structured Three-Phase Treatment Protocol
The clinical delivery of psilocybin-assisted therapy adheres to an intensive, manualized three-phase framework centered on psychological preparation, acute pharmacological dosing, and longitudinal integration. Prior to drug administration, participants undergo comprehensive preparation alongside two dedicated clinicians to establish trust and psychological safety. Each participant spends about eight hours of time in a therapeutic process with two trained clinicians, ensuring that they feel safe, comfortable, and trusting of the environment and the people they're working with prior to taking a high dose of a psychedelic. “We don't want to throw anybody too quickly into that experience without having that safety and trust established,” Dr. Davis explained.
In the second phase—the dosing phase—patients receive one high dose of psilocybin with the two trained therapists who they've been working with. The dosing unfolds over an entire day in the clinic setting. While patients have the experience with psilocybin, they listen to music and are encouraged to “go inward” and experience the emotions that come up during the session. The third phase unfolds in the days and weeks after the dosing, during which they begin to integrate their experiences from the psychedelic session into their day-to-day living. Dr. Davis underscored, “We want to see, not only does it potentially improve depression, but does it improve the way that they can engage in their life?”
This structure ensures continuity of care and provides essential clinical safeguards. Prior research in post-traumatic stress disorder suggests that psychological progress initiated during the preparation phase directly predicts the magnitude of therapeutic response during the dosing session, underscoring that psychotherapy and pharmacological action function as an interdependent package.
Patient Selection, Preliminary Results, and Systemic Biomarkers
Ensuring safety in this trial requires stringent screening parameters. Candidates must display medical stability regarding their underlying oncologic regimen, possess adequate functional bandwidth, and have a reliable social support network. Those with confounding psychiatric comorbidities are excluded.
Preliminary evaluations among the earliest enrolled participants have demonstrated an encouraging safety profile. The primary observed adverse event has been transient post-dose headache, without any serious adverse events, and two of the first three patients experienced clinically meaningful reductions in depressive symptoms.
Beyond mood indices, the study evaluates functional outcomes such as social engagement, quality of life, and treatment adherence, while investigating potential biological mechanisms related to systemic inflammation. As Dr. Davis noted, “There's been some data in preclinical studies in animal models and in pilot studies in humans, showing that there might be some effect of psychedelics on inflammatory biomarkers. Obviously, that's important in cancer care given the role of inflammation in the system, especially its relationship to cognitive decline and other challenges in healing. If it's the case that it has this biological effect, that could potentially point to additional markers of improvement in this population.”
Demonstrating safety and biological viability in this initial pilot will lay the groundwork for future randomized controlled trials designed to establish efficacy and evaluate cost-effectiveness within standard oncology care.
Conclusion
Patients with advanced lung cancer may encounter debilitating psychological distress that impairs quality of life and undermines adherence to life-prolonging antineoplastic treatments. By pairing structured, continuous psychotherapy with supervised psilocybin administration, this pilot trial at The Ohio State University establishes a rigorous protocol designed to address existential distress safely within a medically fragile population. Early signals showing favorable tolerability and clinically meaningful symptom relief underscore the potential of psychedelic-assisted therapies to complement comprehensive cancer care. Future randomized trials will clarify whether these clinical improvements can translate into broader enhancements in patient functioning, systemic inflammatory balance, and overall survivorship.
“I just want to thank our participants,” Dr. Davis concluded. “We wouldn’t be able to do this work if people weren’t willing to give themselves to this process, so we just really want to thank them.”
Key Takeaways
Advanced lung cancer carries high rates of depression, anxiety, and existential distress that are often inadequately managed by standard pharmacotherapies.
The investigational protocol relies on a structured three-phase model consisting of extensive preparation, a supervised high-dose session, and longitudinal integration with two clinicians.
Therapeutic continuity is critical, as initial clinical rapport and psychological unfolding during the preparation phase appear to enhance response during the dosing session.
Early preliminary trial data demonstrate favorable tolerability—with transient headache as the primary side effect—and initial clinically significant reductions in depression.
In addition to measuring mood and treatment adherence, the trial investigates whether classic psychedelics exert systemic biological effects on inflammatory biomarkers relevant to cancer care.
About Dr. Davis
Alan Davis, PhD, is an Associate Professor and the Director of the Center for Psychedelic Drug Research and Education at The Ohio State University. His research focuses on investigating how evidence-based and experimental psychotherapies can help individuals diagnosed with substance use, trauma-related, mood, and anxiety disorders. Dr. Davis incorporates interventions such as motivational interviewing, cognitive behavioral therapy, harm reduction, acceptance and commitment therapy, cognitive processing and prolonged exposure therapies, and psilocybin-assisted psychotherapy into a humanistic and process-oriented approach to improving clinical outcomes.
